Personalised management of alveolar soft part sarcoma: a promising phase 2 study

Lancet Oncol. 2019 Jun;20(6):750-752. doi: 10.1016/S1470-2045(19)30286-4. Epub 2019 May 8.

Authors

Nicolas Penel¹, Yves-Marie Robin², Jean-Yves Blay³

Affiliations

¹ Department of Medical Oncology, Centre Oscar Lambret Lille, 59020 France; Lille University, Lille, France. Electronic address: n-penel@o-lambret.fr.
² Biopathology Unit, Centre Oscar Lambret, Lille, France.
³ Department of Medical Oncology and University Claude Bernard, Léon Bérard Cancer Center, Lyon, France.

PMID: 31078464
DOI: 10.1016/S1470-2045(19)30286-4

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Axitinib
Humans
Sarcoma, Alveolar Soft Part*

Substances

Antibodies, Monoclonal, Humanized
Axitinib
pembrolizumab